CPIX CUMBERLAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1087294 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.7%
TTM net income YoY2,167.1%
TTM EPS YoY1,962.5%
Revenue 3-yr CAGR-13.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.2%
Net margin273.7%
FCF margin-3.9%
EBITDA margin-33.6%
Returns
ROE139.5%
ROA76.6%
ROIC (approx.)-532.4%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.00x
Current ratio3.05x
Interest coverage-47.02x
Cash quality & payout
Operating cash flow / net income-0.01x
Accruals ratio77.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $44.52M | $37.87M |
| Cost of revenue | $6.67M | $6.59M |
| Gross profit | $37.85M | $31.28M |
| R&D expense | $5.57M | $4.82M |
| SG&A expense | $11.95M | $11.13M |
| Operating income | -$2.79M | -$6.43M |
| Interest expense | $495,990 | $605,508 |
| Pretax income | -$2.81M | -$6.47M |
| Income tax | $40,256 | -$22,669 |
| Net income | -$2.84M | -$6.48M |
| EBITDA | $1.35M | -$1.53M |
| EPS (basic) | -0.19 | -0.46 |
| EPS (diluted) | -0.19 | -0.46 |
| Weighted avg. shares (diluted) | 14.85M | 14.06M |
| Balance sheet | ||
| Cash & equivalents | $11.44M | $17.96M |
| Receivables | $16.94M | $11.70M |
| Inventory | $29,935 | $4.00M |
| Current assets | $37.06M | $36.45M |
| PP&E, net | $264,724 | $277,365 |
| Goodwill | $914,000 | $914,000 |
| Intangibles | $53,621 | $17.97M |
| Total assets | $76.82M | $75.58M |
| Current liabilities | $36.74M | $31.62M |
| Short-term debt | $0 | $5.10M |
| Total liabilities | $52.28M | $53.04M |
| Shareholders' equity | $24.88M | $22.85M |
| Shares outstanding | 14.96M | 13.95M |
| Cash flow statement | ||
| Operating cash flow | $4.93M | -$612,186 |
| Capital expenditure | $97,903 | $66,461 |
| Free cash flow | $4.83M | -$678,647 |
| Investing cash flow | -$4.71M | $57,842 |
| Financing cash flow | -$6.75M | $196,904 |
| Depreciation & amortization | $4.15M | $4.90M |
| Stock-based compensation | $408,320 | $301,895 |
| Share buybacks | $263,478 | $579,049 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.